GlaxoSmithKline plc (GSK) Given a GBX 1,550 Price Target by UBS AG Analysts

UBS AG set a GBX 1,550 ($20.38) price target on GlaxoSmithKline plc (LON:GSK) in a research note issued to investors on Tuesday. The firm currently has a neutral rating on the stock.

Several other research firms have also commented on GSK. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.98) price objective on shares of GlaxoSmithKline plc and gave the stock a buy rating in a research note on Tuesday, August 8th. Jefferies Group LLC reissued a buy rating and set a GBX 1,900 ($24.98) price objective on shares of GlaxoSmithKline plc in a research note on Thursday, July 13th. Bryan, Garnier & Co reissued a neutral rating and set a GBX 1,710 ($22.48) price objective on shares of GlaxoSmithKline plc in a research note on Tuesday, September 19th. Deutsche Bank AG set a GBX 1,610 ($21.17) price objective on shares of GlaxoSmithKline plc and gave the stock a neutral rating in a research note on Thursday, September 21st. Finally, J P Morgan Chase & Co dropped their price objective on shares of GlaxoSmithKline plc from GBX 1,750 ($23.01) to GBX 1,570 ($20.64) and set a neutral rating on the stock in a research note on Wednesday, September 13th. Four analysts have rated the stock with a sell rating, eleven have given a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of Hold and an average price target of GBX 1,689.48 ($22.21).

Shares of GlaxoSmithKline plc (GSK) opened at 1515.00 on Tuesday. GlaxoSmithKline plc has a 12-month low of GBX 1,444.00 and a 12-month high of GBX 1,724.50. The company has a 50 day moving average of GBX 1,499.71 and a 200-day moving average of GBX 1,587.03. The firm’s market cap is GBX 74.05 billion.

WARNING: This piece of content was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://sportsperspectives.com/2017/10/11/glaxosmithkline-plc-gsk-given-a-gbx-1550-price-target-by-ubs-ag-analysts.html.

The business also recently disclosed a dividend, which will be paid on Thursday, October 12th. Stockholders of record on Thursday, August 10th will be issued a dividend of GBX 19 ($0.25) per share. The ex-dividend date is Thursday, August 10th. This represents a dividend yield of 1.23%.

In other GlaxoSmithKline plc news, insider Manvinder Singh Banga bought 2,267 shares of GlaxoSmithKline plc stock in a transaction on Wednesday, July 26th. The stock was acquired at an average cost of GBX 1,599 ($21.02) per share, with a total value of £36,249.33 ($47,658.86). Also, insider Patrick Vallance bought 861 shares of GlaxoSmithKline plc stock in a transaction on Friday, July 14th. The shares were acquired at an average cost of GBX 1,618 ($21.27) per share, with a total value of £13,930.98 ($18,315.78). Over the last ninety days, insiders have acquired 3,144 shares of company stock valued at $5,042,191.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply